Optimizing dendritic cell-based approaches for cancer immunotherapy

Jashodeep Datta, Julia H. Terhune, Lea Lowenfeld, Jessica A. Cintolo, Shuwen Xu, Robert E. Roses, Brian J. Czerniecki

Research output: Contribution to journalArticlepeer-review

42 Scopus citations


Dendritic cells (DC†) are professional antigen-presenting cells uniquely suited for cancer immunotherapy. They induce primary immune responses, potentiate the effector functions of previously primed T-lymphocytes, and orchestrate communication between innate and adaptive immunity. The remarkable diversity of cytokine activation regimens, DC maturation states, and antigen-loading strategies employed in current DC-based vaccine design reflect an evolving, but incomplete, understanding of optimal DC immunobiology. In the clinical realm, existing DC-based cancer immunotherapy efforts have yielded encouraging but inconsistent results. Despite recent U.S. Federal and Drug Administration (FDA) approval of DC-based sipuleucel-T for metastatic castration-resistant prostate cancer, clinically effective DC immunotherapy as monotherapy for a majority of tumors remains a distant goal. Recent work has identified strategies that may allow for more potent “next-generation” DC vaccines. Additionally, multimodality approaches incorporating DC-based immunotherapy may improve clinical outcomes.

Original languageEnglish (US)
Pages (from-to)491-518
Number of pages28
JournalYale Journal of Biology and Medicine
Issue number4
StatePublished - Dec 12 2014
Externally publishedYes


  • Cancer
  • Chemotherapy
  • Combination therapy
  • Dendritic cell
  • Immunotherapy
  • Vaccine

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)


Dive into the research topics of 'Optimizing dendritic cell-based approaches for cancer immunotherapy'. Together they form a unique fingerprint.

Cite this